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Insulin Therapy and Autoimmune 
Disease with Relevance to Non 
Alchoholic Fatty Liver Disease
Ian James Martins
Abstract
The diabetes epidemic is now expected by the year 2050 to become a global 
pandemic with approx. 592 million affected in both the developed and developing 
world. The treatment of diabetes by insulin therapy has been the focus for many 
diabetics with the improvement and prevention of various diseases such as cardio-
vascular disease, kidney disease and neurodegeneration. The global nonalcoholic 
fatty liver disease (NAFLD) epidemic has now become of major concern to diabetes 
with critical interest in insulin therapy to reverse and stabilize autoimmune disease 
with relevance to NAFLD and the diabetes pandemic. Dietary components that acti-
vate anti-aging genes improve insulin therapy and should be assessed with specific 
amounts and doses of Indian spices consumed that may not interfere with insulin 
therapy and induce mitophagy in various diseases. Food quality, appetite control 
and core body temperature are critical to maintain insulin therapy with unhealthy 
diets linked to NAFLD and diabetes. Genomic medicine and dietary activators are 
essential to maintain insulin therapy and prevent toxic immune reactions with 
relevance to NAFLD and diabetes management.
Keywords: insulin therapy, genomic, autoimmune disease, diabetes, global, 
mitophagy, curcumin, cinnamon
1. Introduction
The diabetes epidemic is expected to affect approx. 592 people by the year 2035. 
The urgency to prevent the largest diabetes epidemic in history has now assessed 
multiple risk factors involved with induction of Type 3 diabetes connected to 
various chronic diseases. Insulin resistance and brain aging now indicate neuron 
vulnerability to mitophagy associated with the diabetes pandemic expected in 2050 
[1, 2]. Diabetes and its connections autoimmunity [3] have become important to 
mitophagy, metabolic disease with relevance to the nonalcoholic fatty liver disease 
(NAFLD) epidemic.
An association between various genes and the immune system [4, 5] has been 
proposed to be involved with the regulation of life-span in various species. Immune 
gene activation has been associated with brain aging [6] with the critical involve-
ment of inflammation in the development of neuro-degeneration. Autoimmune 
disease, drugs and immunosenescence are related to the chronic disease epidemic 
with uncontrolled release of inflammatory cytokines such as tumor necrosis factor 
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α and interleukin-6 [7, 8]. Major interests to determine human longevity require 
the assessment of nutrition and diet with relevance to the control of inflammatory 
cytokines that are associated with age-related changes in the immune system and 
the induction of diabetes, NAFLD and neurodegeneration.
Appetite control with relevance to immuno-metabolism has become critical 
to the treatment of NAFLD. The major defect in global chronic disease is autoim-
mune disease with defective adipose tissue and liver interaction involved with the 
release of inflammatory cytokines and adipo-cytokines relevant to toxic immune 
reactions that involve the pancreas, brain, heart, thyroid, kidneys and reproductive 
organs. Appetite control and autoimmune disease are connected to anti-aging genes 
with relevance to irreversible programmed cell death in various cells and tissues. 
Immune competence changes over a human’s life span with a process known as 
immunosenescence [9, 10]. In man multiple theories of aging have been proposed 
with the immune theory of aging that involve abnormal inflammatory responses 
that contribute to the induction of chronic diseases [11].
In various communities in the developing and developed world the understand-
ing of the ingestion of a healthy diet and hepatic fat metabolism has become of 
critical importance to the treatment diabetes that is now linked to various organ 
diseases. In the world [12] transition to healthy diets has become urgent to prevent 
insulin resistance, autoimmune disease and NAFLD. The liver is the major organ for 
the metabolism of dietary fat and after consumption of a meal in healthy individu-
als the fat is rapidly metabolized by the mitochondria in the liver.
A diet rich in fat and sugar that lead to fat deposition in the liver can be referred 
to as liver steatosis. The defect in the liver fatty acid metabolism is possibly related 
to mitochondrial dysfunction and a careful calorie controlled diet may reverse liver 
steatosis. As mitochondrial apoptosis occurs steatohepatitis may be associated with 
liver inflammation. Steatohepatitis may induce NAFLD that may then progress to 
severe inflammation and liver cirrhosis. In obesity and diabetes the metabolism 
of a fat meal by the liver is defective with associated hyperglycemia and hyperin-
sulinemia. Food restriction [13] and appetite control are vital to the treatment of 
NAFLD with hepatic fat metabolism connected to insulin resistance, autoimmune 
disease and mitophagy [14].
2. Diabetes and pathogenetic loop complications
Insulin treatment in diabetes has provided information that approx. 30% of 
patients are involved with insulin treatment or plan to start insulin with insulin 
regimens [15] associated with various insulin doses and failure of oral anti-diabetic 
medications. Type 2 diabetes mellitus is characterized by hyperglycemia, insulin 
resistance, and impairment of insulin secretion [16]. The impairment of insulin 
secretion is related to hyperglycemia, high serum low-density lipoprotein cholesterol 
concentrations and low serum high-density lipoprotein cholesterol concentrations 
with relevance to cardiovascular disease [17]. The relative importance of impaired 
insulin release and insulin resistance in the pathogenesis of Type 2 diabetes has been 
evaluated and may be connected to NAFLD. NAFLD may be connected to autoim-
mune disease and mitophagy associated with impairment in insulin secretion and 
cardiovascular disease [18–20]. In Type 1 diabetes the use of insulin therapy has been 
assessed with the critical importance to reduce hyperglycemia, severe hypoglycemia 
and the development of long-term complications [21–23]. Insulin therapy should 
be carefully evaluated in Type 1 and Type 2 diabetes with relevance to reduction in 
plasma glucose levels [24]. Interference in hepatic glucose production [24, 25] or 
interference with increased glucose uptake by the liver may be sensitive to repression 
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of glucose related genes associated with the induction of glucolipotoxicity, NAFLD 
and insulin resistance. Exercise and insulin therapy [26] may reduce glucolipotoxic-
ity and NAFLD but with the aging process the pathogenetic loop [27–32] that involve 
hyperglycemia, hypercholesterolemia and hyperinsulinemia may be associated with 
autoimmune disease, mitophagy and programmed cell death of various cells and 
tissues [18–20]. The role of diet, lifestyle, stress, sleep and circadian disorders [33] 
may inactivate the anti-aging gene Sirtuin 1 (Sirt 1) with relevance to insulin therapy 
and induction of NAFLD associated with the pathogenetic loop (Figure 1) and 
uncontrolled inflammation of cells and tissues [18–20].
3.  Anti-aging genes, mitochondrial apoptosis and programmed cell 
death
Insulin resistance is involved early in alterations of nuclear, subcellular and cell 
membrane function that lead to cell transformation without reversible changes 
with accelerated cell apoptosis [34]. In 2050 the predicted global diabetes pandemic 
[1, 2] has accelerated scientific research to determine the identification of novel 
genomic pathways such as the anti-aging gene Sirt 1 that may provide new knowl-
edge with relevance to accelerated cell apoptosis and inactivated insulin therapy. 
In Type 2 diabetes and Type 1 diabetes various genes and genetic loci have been 
Figure 1. 
Diabetes and the pathogenetic loop associated with inflammation, age related diseases and neurodegeneration 
involve inactivation of the anti-aging gene Sirtuin 1 (Sirt 1) associated with mitochondrial apoptosis in various 
species and man.
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reported to be involved in the development of diabetes [35]. Novel genes [36] have 
been identified that are involved with autoimmune disease [18, 19, 36, 37] and glu-
colipotoxicity with irreversible immune complications relevant to NAFLD, diabetes 
[3] and the pathogenetic loop. The discovery of the anti-aging gene Sirt 1 now has 
become important to the treatment of diabetes with insulin therapy in Type 1 and 
Type 2 diabetes connected to Sirt 1 activation in the pancreas with relevance to 
insulin release [38] with Sirt 1 associated with mitochondrial biogenesis (Figure 1) 
and cell survival in various tissues [38, 39]. The inactivation of Sirt 1 [39] in humans 
leads to the pathogenetic loop in diabetes and implicates nutritional and environ-
mental factors in the induction of programmed cell death.
Sirt 1 is a nicotinamide adenine dinucleotide (NAD+) dependent class III histone 
deacetylase (HDAC) that targets transcription factors such as p 53 to adapt gene 
expression to metabolic activity and the deacetylation of nuclear receptors indicate 
its critical involvement in insulin resistance and autoimmune disease [18]. In situ 
hybridization analysis has localized the human Sirt 1 gene to chromosome 10q21.3 
[18]. Calorie restriction is essential for Sirt 1 transcriptional regulation with other 
factors such as diet and lifestyle critical for the prevention of insulin resistance and 
NAFLD. Sirt 1 is an acute phase protein involved with neuron proliferation [18] 
and its regulation of the suprachiasmatic nucleus is involved with control of the 
circadian rhythm [18]. The circadian rhythm and immune system are closely con-
nected to the immune response. Nutritional interventions that are controlled by the 
consumption of a low calorie diet indicate the maintenance of connections between 
Sirt 1 and other anti-aging genes such as Klotho, p66shc (longevity protein) and 
FOXO1/FOXO3a that are connected to programmed cell death [36]. Sirt 1 and 
transcriptional regulation of anti-aging genes are critical to mitophagy (Figure 1) 
and neurodegenerative disease with accelerated brain aging connected to NAFLD 
and diabetes [19, 36].
4.  Insulin therapy and Indian spices with relevance to NAFLD and 
diabetes
The connections between NAFLD and diabetes have become of central impor-
tance to the expected diabetes pandemic by the year 2050 [1, 2]. NAFLD in diabetic 
individuals may completely inactivate insulin therapy with defective insulin dose 
regimens and failure of oral anti-diabetic medications. The defect in the liver fatty 
acid metabolism is possibly related to mitochondrial dysfunction associated with 
severe liver inflammation and steatohepatitis that may induce NAFLD that may 
then progress to severe inflammation (NASH) and liver cirrhosis. Insulin therapy 
has been used to improve liver function but with NAFLD, high dose insulin therapy 
may be unsuccessful with liver inflammation [40–42] associated with uncontrolled 
hyperglycemia and mitochondrial apoptosis (Figure 2). Insulin therapy with insulin 
dose and oral anti-diabetic medications should be re-evaluated to improve hepato-
cyte mitochondrial biogenesis with relevance to reversal of liver disease connected to 
hyperglycemia and NAFLD in various Type 1, Type 2 and Type 3 [35, 39] diabetics.
The connections between Sirt 1 and insulin resistance have accelerated in recent 
years with Sirt 1 as a calorie sensitive gene is now implicated in insulin resistance 
and to the important to glucose dependent insulin secretion with protection of 
pancreatic β-cell mass [43–46]. Sirt 1 may be involved in silencing insulin resistance 
by regulation of specific proteins involved in insulin action [47]. Anti-inflammatory 
actions in adipocytes involve Sirt 1 repression and inflammation [48, 49] associ-
ated with the adipose-liver defect [49, 50] and the induction of NAFLD. Sirt 1 
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dysfunction in the brain leads to systemic insulin resistance [51] with close links 
to Type 3 diabetes and NAFLD [52, 53]. In Sirt 1 knockout mice increased adipose 
tissue mass has been connected to NAFLD [33]. The expression of Sirt 1 protein 
has a molecular weight (Mol Wt) of 81 kda with Mol Wt variation (81–110 kda). 
Insulin therapy to prevent NAFLD requires insulin dose/antidiabetic medication 
calculation to release the Sirt 1 acute phase protein [18, 37]. Sirt 1 is essential to 
prevent inflammation and Sirt 1 inactivation may induce NAFLD that may corrupt 
pancreas function. Insulin therapy and plasma Sirt 1 levels may allow mitochondrial 
biogenesis to be assessed with relevance to therapeutic glucose control in Type 1, 
2 and 3 diabetics. It is unclear if inactivation of insulin therapy is associated with 
mitophagy and the induction of NAFLD and various organ diseases [52]. Appetite 
control [13, 18] is now critical to the maintenance of mitochondrial biogenesis and 
insulin therapy with overeating [13] connected to inactivation of insulin therapy 
and linked to the severity of the diabetic condition.
Indian spices have become important as a diabetes technology [54] with Indian 
spices such as curcumin and cinnamon associated with glucose control in diabet-
ics (Figure 2). The event of insulin therapy as the primary therapy in diabetes 
technology has raised concern with relevance to the consumption of Indian spices 
as a secondary technology [55]. Indian spices consumed over many years are not 
cleared from the body and may bind to cells and receptors with excess Indian spices 
that may associate with insulin receptors related to altered insulin actions and 
inactivated insulin therapy. In normal individuals consumption of cinnamon and 
curcumin may inactivate the biological activity of insulin [54, 55] with Indian spices 
as the secondary treatment for glucose control in the brain and the periphery. Drugs 
such as anti-obese drugs [56] and novel drugs [57] are now of critical importance 
to NAFLD and insulin therapy. Insulin therapy and the use of various therapeutic 
drugs in diabetes have been linked to the treatment of organ dysfunction [35, 57–59] 
in diabetes. The use of Indian spices should be reassessed in various populations to 
Figure 2. 
Indian spices have become important as a diabetes technology and its use in diabetes has become of concern. 
Indian spices such as curcumin and cinnamon associated with glucose control in diabetics but excessive 
curcumin or piperine may inactivate insulin therapy associated with hyperglycemic induced mitochondrial 
apoptosis in the brain and the periphery.
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prevent interference with drug/insulin therapy (Figure 2) or with caffeine effects 
[60] relevant to the treatment of NAFLD and diabetes. The mixing of spices such 
as curcumin, turmeric and black pepper in coffee should be discouraged and may 
contribute to the transcriptional dysregulation of Sirt 1 and induction of mitochon-
drial apoptosis relevant to diabetes and the pathogenetic loop [27–32].
5.  Genomic medicine and Sirt 1 activators reverse immune reactions  
in global chronic disease
Genomic medicine in the treatment of cardiovascular disease and diabetes  
[19, 37] has now accelerated in various communities. Peripheral nutrition is essen-
tial early to prevent neurodegeneration (Type 3 diabetes) that lead to uncontrolled 
peripheral glucose homeostasis. Type 3 diabetes is associated with suprachiasmatic 
nucleus defects with the abnormal maintenance of brain and whole body glucose 
metabolism in various species and man [20]. Nutritional therapy in diabetics now 
need to involve the use of Sirt 1 activators [61] to prevent the effects of various Sirt 
1 inhibitors that accumulate in the blood plasma that repress Sirt 1 expression in 
cells and tissues. A dose of 4 g/day of phosphatidylinositol [62] is essential with 
insulin therapy to prevent hyperglycemia, NAFLD and other neurodegenerative 
diseases. Sirt 1 inhibitors such as excess palmitic acid (cream, cheese), alcohol and 
drugs (suramin and sirtinol) should be carefully controlled to prevent inactivation 
of insulin therapy. Sirt 1 activators such as pyruvic acid, leucine and magnesium 
are critical with relevance to insulin therapy. Diabetic individuals with Indian spice 
consumption (Figure 3) over years need to be carefully evaluated with relevance 
to plasma Sirt 1 inhibitors, xenobiotics [63], caffeine content [60], drug therapy, 
bacterial lipopolysaccharides (LPS) and mycotoxins [62] that may interfere with 
insulin/oral medication therapy. The importance of genomic medicine may indicate 
that the immune system may malfunction [37] early with relevance to poor nutri-
tion of food quality with irreversible organ disease manifestations. Biotherapy 
and the immune system [37, 61] may be critical to insulin therapy and connected 
to insulin resistance and NAFLD. Appetite control and essential food components 
[64] may be essential to maintain the immune system with autoimmune disease 
Figure 3. 
Poor food quality and core body temperature defects will inactivate Sirt 1 and induce insulin resistance 
and NAFLD. Sirt 1 inhibitors such as xenobiotics, caffeine/Indian spice over-consumption and magnesium 
deficiency may lead to the diabetes pandemic with high doses of phosphatidylinositol essential to maintain 
insulin therapy and prevent the induction of NAFLD.
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associated with appetite dysregulation and poor food quality. Specific mitochon-
drial nutrients [65] with insulin therapy need to be consumed to prevent severe 
mitophagy and organ disease.
Food quality with relevance to stroke, synaptic plasticity and neurological 
diseases has become important to diabetic individuals with essential maintenance 
and prevention of brain diseases by insulin therapy. Unhealthy diets that contain 
LPS, mycotoxins and xenobiotics can induce NAFLD with inactivation of insulin 
therapy. In the developing world increased plasma LPS levels (Figure 3) have raised 
concern with relevance to induction of metabolic and neurodegenerative diseases 
[66, 67]. Antibiotic resistance with relevance to antimicrobial drug use should be 
carefully controlled to prevent excessive release of LPS from the debris of gram 
negative bacteria [68]. Food preparation should be carefully assessed to prevent end 
products such as LPS and patulin that may persist in contaminated food  
[63, 69]. LPS and patulin may inactivate Sirt 1 [62] with relevance to insulin resis-
tance and NAFLD. Xenobiotics [63] in air, food and water may inactivate insulin 
therapy (Figure 3) with increased xenobiotic levels associated with mitochondrial 
apoptosis.
Core body temperature (Figure 3) and insulin therapy are closely connected 
and dysregulation of core body temperature may induce NAFLD. The discovery of 
the heat shock gene Sirt 1 [70] has indicated that careful body temperature control 
is critical to prevent autoimmune disease and mitochondrial apoptosis. Sirt 1 and 
its inactivation are associated with increased heat shock protein 70 with relevance 
to natural killer cell activation and mitochondrial apoptosis. Nutritional therapy 
and core body temperature are essential to maintain insulin therapy in diabetics 
with relevance to mitophagy and programmed cell death. The event of heat shock 
protein 70 disturbances may lead to kidney injury [71] and associated with chronic 
kidney disease and neurodegeneration in diabetes.
6.  Novel biomarkers and insulin therapy may reverse NAFLD and 
diabetes
The analysis of various plasma biomarkers with insulin therapy [72] has become 
of major interest to NAFLD development, therapeutic strategies [73–77] and diabe-
tes research. Essential measurements of plasma Sirt 1 and heat shock protein levels 
need to be determined to indicate core body temperature defects with relevance to 
inactivation of insulin therapy. Tissue analysis of anti-aging genes [18, 33, 54] need 
to be conducted to determine the role of insulin therapy with relevance to reversal of 
NAFLD [18, 33, 35, 49, 55, 68, 69] with connections to inflammation and metabolic 
diseases. Plasma assays of inflammatory cytokines such as tumor necrosis factor 
alpha, interleukin-1 and interleukin-6 [10, 11] need to be assayed with effective 
insulin therapy. The major limitation with insulin therapy is to correlate the dose of 
insulin injected with plasma biomarkers [78] that maintain mitochondrial biogen-
esis associated with the prevention of NAFLD (Figure 4). The use of antimicrobials 
[79] with insulin therapy should be carefully controlled to prevent increased release 
of gram negative bacteria LPS end products that may interfere with glucose homeo-
stasis and induce NAFLD. Plasma LPS should be measured with antimicrobial use in 
individuals on insulin therapy. The connections between the antimicrobial activity, 
immune system and nitric oxide homeostasis involve Sirt 1 and connected to toxic 
immune reactions [80].
The geriatric population in many communities is associated with insulin resis-
tance, Sirt 1 repression and nuclear-mitochondria defects relevant to NAFLD. Sirt 
1 measurement in the plasma, cytoplasm and nucleus are essential to determine 
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the relevance of insulin therapy and mitochondrial apoptosis when compared 
to the validity of various diagnostic tests and plasma analytic measurements. In 
many biomarker laboratories the comprehensive assessment of various biomarkers 
may not be correlated with insulin therapy with mitophagy the inevitable cellular 
defect in geriatric individuals. Analysis of plasma biomarkers (Figure 4) and tissue 
samples may indicate a primary autoimmune reaction related to a defective nuclear-
mitochondria interaction.
Insulin therapy and its use should be carefully revised with relevance to con-
ventional plasma tests that do not indicate cellular mitophagy and toxic immune 
reactions associated with diabetes [81, 82]. Previous studies [83, 84] with the 
assessment of the role of insulin on cytokines, lymphocytes and macrophages do 
not assess Sirt 1’s role in toxic immune reactions and mitophagy. Recent studies 
have shown that molecular lipid biomarkers from lipidomic analysis [85–88] may 
determine diabetes severity. The role of insulin therapy with relevance to lipidomic 
biomarkers may integrate routine plasma biomarker testing with relevance to cel-
lular Sirt 1 expression and plasma Sirt 1 analysis (Figure 4).
7. Conclusion
Insulin treatment has been evaluated in diabetes but the global NAFLD epidemic 
that is expected to reach between 20 and 30% of the worldwide communities will 
now be connected to diabetes pandemic and the pathogenetic loop. Insulin therapy 
has been assessed with relevance to improvement in inflammatory conditions but 
the defect in the anti-aging gene Sirt 1 and diabetic mitophagy still persists with the 
induction of NAFLD and various organ diseases. Insulin therapy with Indian spice 
consumption requires reassessment to avoid over-consumption of Indian spices 
that may inactivate insulin therapy and mitochondrial biogenesis. Food quality, 
appetite control and core body temperature are critical to maintain insulin therapy 
with unhealthy diets linked to NAFLD and diabetes. Genomic medicine and Sirt 
1 activators are essential to maintain insulin therapy in the developing world with 
toxic immune reactions important to NAFLD. Insulin therapy may not reverse the 
nuclear-mitochondria defect that is relevant to global organ disease and various 
plasma biomarkers.
Figure 4. 
Complications of insulin therapy in diabetes lead to irreversible mitophagy and programmed cell death with 
relevance to defective Sirt 1 expression in diabetic individuals. Conventional clinical biochemistry tests do not 
indicate nuclear-mitochondria defects associated with autoimmune disease and mitophagy but lipidomic tests 
may be relevant to insulin therapy and Sirt 1 analysis.
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